Drugs / Metirapone
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06801249 | Feb 2021 → Nov 2024 overdue | Cushing syndrome, adrenal gland disorder | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Metirapone | “Metirapone is an inhibitor of the enzyme 11-β-adrenal hydroxylase, which is deputed to catalyze the conversion of 11-desoxycortisol (11-S) to cortisol and...” NCT06801249 ↗ |
| Action | Inhibit | “Metirapone is an inhibitor of the enzyme 11-β-adrenal hydroxylase” NCT06801249 ↗ |